Roy Baynes, MD, PhD
The European Medicine Agency’s Committee for Medicinal Products for Human Use has granted a positive opinion to olaparib (Lynparza) tablets as monotherapy for the treatment of adult patients with germline BRCA1/2
-mutant, HER2-negative locally advanced or metastatic breast cancer.1
If approved, olaparib would be indicated for those who were previously been treated with an anthracycline and a taxane in the neoadjuvant, adjuvant, or metastatic setting unless they weren’t suitable for these therapies. Additionally, patients with hormone receptor (HR)–positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy, said AstraZeneca, the company that co-develops olaparib with Merck, in a press release.
... to read the full story